CRF1 antagonists previously have been assessed in the treatment of depression and anxiety (Zobel et al. 2000) and Phase II/Phase III clinical trials with these agents currently are underway for the treatment of alcohol use disorders (www.clinicaltrials.gov; Zorrilla and Koob 2010). Here, CRHR1 is linked to Anxiety.